Markets:

Overview

News

Currencies

International

Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

14.89 -0.29 (-1.91%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about HUTCHMED (China) Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

March 14, 2024

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday.

Via Benzinga

Topics Stocks

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 13, 2024

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 13, 2024

Via Benzinga

Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket ↗

March 13, 2024

Shares of SurgePays, Inc. (NASDAQ: SURG) fell sharply in today’s pre-market trading after the company reported worse-than-expected fourth-quarter financial results.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

March 13, 2024

Pre-market stock movers are a great way to start the day with all of the hottest news worth reading about on Wednesday morning!

Via InvestorPlace

Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗

March 13, 2024

U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.

Via Benzinga

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

February 28, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

February 14, 2024

U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 80 points on Wednesday.

Via Benzinga

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

February 06, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets ↗

February 03, 2024

Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.

Via Talk Markets

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

February 02, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED to Announce 2023 Final Results

February 01, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

January 29, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

January 10, 2024

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

December 12, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

November 30, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday ↗

November 24, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Goldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Know ↗

November 10, 2023

Via Benzinga

Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing

November 10, 2023

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

November 08, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade ↗

November 08, 2023

On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier.

Via Investor's Business Daily

Rocket Pharmaceuticals Stock Sees Improved Price Strength ↗

November 02, 2023

On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78

Via Investor's Business Daily

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

November 01, 2023

Virtual Investor Conference on November 8th and 9th, 2023

From Virtual Investor Conferences

Via GlobeNewswire

Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90 ↗

October 31, 2023

Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 30, 2023

Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.

Via Benzinga

Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday ↗

October 30, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher ↗

October 27, 2023

A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday ↗

October 27, 2023

U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Apellis Pharmaceuticals Stock Shows Rising Relative Strength ↗

October 24, 2023

A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue?

Via Investor's Business Daily

Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90 ↗

October 16, 2023

Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

All News about HUTCHMED (China) Limited - American Depositary Shares

Starting at $3.75/week.

Subscribe Today